September 29, 2022

| Source: DelveInsight Business Research LLP DelveInsight Business Research LLP
New Delhi, INDIA
Los Angeles, USA, Sept. 06, 2021 (GLOBE NEWSWIRE) — Periodontal Disease Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight
The majority of the drugs for Periodontal disease are in the early and mid-stages of development. So, in the coming years, the market is expected to grow with the launch of these drugs. 
DelveInsight’s “Periodontal Disease Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Periodontal Disease pipeline landscapes. It comprises Periodontal Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Periodontal Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Periodontal Disease pipeline products. 
Some of the key takeaways from the Periodontal Disease Pipeline Report  
Get an overview of pipeline landscape @ Periodontal Disease Clinical Trials Analysis 
Periodontal Diseases mainly result from infections and inflammation of the gums and bones that surround and support the teeth.
Periodontal Disease Emerging Drugs
AMY-101 is a novel complement of C3-targeted therapeutics based on the 3rd-generation compstatin analog Cp40. Compstatins prohibit complement centrally, at the level of C3, and inhibit all downstream pathways of the complement activation cascade. It is currently in the Phase II stage of development, but its Phase III trial is planned. 
AL102-PDT is a botanical drug that prohibits tooth loss by blocking MMP-1, -8, -9, and -13. The efficacy of AL102-PDT was proven in ligature-induced periodontitis observed in beagle dogs. The efficacy is better than Doxycycline, a commercial MMP inhibitor, which the FDA approved for periodontitis. It is currently in the Phase I stage of development for periodontitis.  
Denteric is developing vaccines targeting major virulence factors produced by the bacterium Porphyromonas gingivalis (P. gingivalis) and related species. In so doing, the company’s primary goal is to provide options to treat and prevent severe periodontal disease and its complications. It was originally discovered by CSL Behring and was then out-licensed to Denteric. It is currently in the Preclinical stage of development. 
P4M01 is an antimicrobial peptide for periodontal disease, microbiota-related disorders, and potentially, Alzheimer’s disease prevention. It has completed a Phase II clinical trial study. 
For further information, refer to the detailed report @ Periodontal Disease Pipeline Therapeutics 
Scope of Periodontal Disease Pipeline Drug Insight    
·       Periodontal Disease Therapies Late-stage (Phase III)  
·       Periodontal Disease Therapies Mid-stage (Phase II)
·       Periodontal Disease Therapies Early-stage (Phase I) 
·       Periodontal Disease Preclinical stage and Discovery candidates     
·       Discontinued and Inactive candidates  
·  Paracrine communication modulators; Proto oncogene protein c akt modulators; SIRT1 protein stimulants
·   Peptide hydrolase inhibitors
·   Complement C3 inhibitors
·   Immunostimulants 
·     Peptides
·    Small molecules 
·    Vaccine
·    Proteins
·     Parenteral 
·      Oral
·      Subgingival
·       Monotherapy
·       Combination
·       Mono/Combination 
Key Questions regarding Current Periodontal Disease Treatment Landscape and Emerging Therapies Answered in the Pipeline Report  
Table of Contents
Get a customized pipeline report @ Periodontal Disease Drugs Pipeline Report  
Other Reports
Browse Blog Posts   
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

source

Leave a Reply